header
Image from OpenLibrary

Clinico-pharmacological study of low dose capecitabine and oxaliplatin versus standard XELOX in metastatic colorectal cancer / Raghda Yahia Abuelela ; Supervised Mostafa Mahmoud Elserafi , Samia Abdelsamee Shouman , Maha Yahia Ismail

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Raghda Yahia Abuelela , 2020Description: 178 P. : charts ; 25cmOther title:
  • في علاج أورام القولون والمستقيم المتقدمه XELOXدراسه فارما إكلينيكيه لمقارنه إستخدام الكابسيتبين والأوكسالبلاتين بجرعات منخفضه وإستخدام برتوكول [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) Summary: Background: Colorectal cancer (CRC) is the fourth most common human malignancy, and the leading cause of cancer related deaths worldwide. Conventional chemotherapy is normally administered near the maximal tolerated dose while metronomic chemotherapy refers to more frequent administration of chemotherapeutics at doses significantly less than the maximum tolerated dose, with no prolonged drug-free breaks Aims: To compare between low dose metronomic chemotherapy with Capecitabine and Oxaliplatin is and classic XELOX in treatment of metastatic Colorectal cancer regarding response rates, toxicity and pharmacokinetics. Methods:This is a randomized phase II prospective cohort study that included 70 metastatic colo-rectal cancer patients diagnosed at National Cancer Institute (NCI), Cairo University between January 2016 and June 2017. Results: The median duration of the treatment for each arm was 6 months.Toxicity occurred in 26 cases (75 % of arm A) and 21 cases (60% of arm B), The median TTP for patients receiving arm A was 7.6 months while the patients receiving arm B had median TTP 5.7 months (P=0.318) while the median OS for Arm A 15.9 and for Arm B (15.8) (p=0.8) that is insignificant.Conclusion: Metronomic protocol was associated with lower rates of toxicity, better pharmacokinetics profile without improvements in PFS or OS
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2020.Ra.C (Browse shelf(Opens below)) Not for loan 01010110080979000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2020.Ra.C (Browse shelf(Opens below)) 80979.CD Not for loan 01020110080979000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)

Background: Colorectal cancer (CRC) is the fourth most common human malignancy, and the leading cause of cancer related deaths worldwide. Conventional chemotherapy is normally administered near the maximal tolerated dose while metronomic chemotherapy refers to more frequent administration of chemotherapeutics at doses significantly less than the maximum tolerated dose, with no prolonged drug-free breaks Aims: To compare between low dose metronomic chemotherapy with Capecitabine and Oxaliplatin is and classic XELOX in treatment of metastatic Colorectal cancer regarding response rates, toxicity and pharmacokinetics. Methods:This is a randomized phase II prospective cohort study that included 70 metastatic colo-rectal cancer patients diagnosed at National Cancer Institute (NCI), Cairo University between January 2016 and June 2017. Results: The median duration of the treatment for each arm was 6 months.Toxicity occurred in 26 cases (75 % of arm A) and 21 cases (60% of arm B), The median TTP for patients receiving arm A was 7.6 months while the patients receiving arm B had median TTP 5.7 months (P=0.318) while the median OS for Arm A 15.9 and for Arm B (15.8) (p=0.8) that is insignificant.Conclusion: Metronomic protocol was associated with lower rates of toxicity, better pharmacokinetics profile without improvements in PFS or OS

Issued also as CD

There are no comments on this title.

to post a comment.